TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10764703
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for one week (H pylori eradication group)
Study: 10764703
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for 12 months (H pylori positive group)
Study: 10764703
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (H pylori negative control group)
Study: 8834976
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg at bedtime
Study: 1349028
Drug: TRZ alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRZ alone (5.0 mg)
Study: 1349028
Drug: TRZ+MCTZ-2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRZ+MCTZ-2.5 mg
Study: 1349028
Drug: TRZ+MCTZ-5.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRZ+MCTZ-5.0 mg
Study: 6146258
Drug: Anticoagulants, platelet-active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists
Study: 26982282
Drug: Cream (for
Normalized name: Cetaphil Moisturizing Body Cream (For Dry,Sensitive Skin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (for infants with BPD)
Study: 21105887
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin for 3 days (U group)
Study: 21105887
Drug: 4-week levofloxacin-azithromycin
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week levofloxacin-azithromycin combination (P group)
Study: 21105887
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with both azithromycin and 4-week levofloxacin-azithromycin (U+P group)
Study: 18599162
Drug: Blended learning
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended learning program (including e-learning) administered to 26 new nurses
Study: 10711075
Drug: Control (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (regular insulin)
Study: 7574775
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)
Study: 7574775
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of methotrexate (MTX)
Study: 7574775
Drug: Intraarterial (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial (IA) administration of MTX
Study: 7574775
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of MTX
Study: 21751861
Drug: High-volume (170
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume (170 mL) ropivacaine (0.2%) with epinephrine (1:100,000)
Study: 19504141
Drug: Clopidogrel hydrogensulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogensulfate (CHS, 300 mg loading, followed by 75 mg/day)
Study: 19504141
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (CB, 300 mg loading, followed by 75 mg/day)
Study: 19504141
Drug: Clopidogrel hydrogensulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogensulfate (CHS, 5 micromol/L ADP)
Study: 19504141
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (CB, 5 micromol/L ADP)
Study: 15504308
Drug: Omeprazole (OME)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OME) 20 mg
Study: 11096461
Drug: vit C‐1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: vit C‐1500 (1500 mg/day)
Study: 11096461
Drug: vit C‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: vit C‐500 (500 mg/day)
Study: 9151231
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT) using p-boronophenylalanine (BPA) at a dose of 250 mg BPA/kg body weight during a 2-hour infusion.
Study: 3533568
Drug: nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (10 mg X 5)
Study: 15816573
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 mL (Group S)
Study: 10619585
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g elemental calcium, twice daily for 16 weeks)
Study: 10619585
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 16 weeks)
Study: 1921241
Drug: Intravenous zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous zinc supplementation for 8 weeks
Study: 26050650
Drug: Vincristine-steroid pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine-steroid pulses during maintenance
Study: 21610711
Drug: Oral temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide (200 mg m(‐2) per day; days 1‐5)
Study: 21610711
Drug: Intravenous dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dacarbazine (800 mg m(‐2); day 1)
Study: 1837121
Drug: Horse ALG
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse ALG 15 mg/kg just before transplant surgery; ALG 12 mg/kg on the first day after transplant followed by 4 doses of 10 mg/kg on alternate days; CyA p.o 8 mg/kg/d; prednisone 0.25 mg/kg/d
Study: 1837121
Drug: OKT3 5
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 5 mg just before transplant followed by 4 doses of 5 mg/d.; CyA and prednisone were administered using the same schedule as group A
Study: 6819969
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) with low-dose prednisone
Study: 31526670
Drug: VMATAuto (automatically
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMATAuto (automatically generated volumetric modulated arc therapy plans)
Study: 19898645
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 0.03 mmol BQ123 (selective endothelin A-receptor blocker)
Study: 17763271
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of (1/2) normal saline (NS) at a rate of 1000 mL/h for two hours
Study: 17763271
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of (1/2) NS at 10 mL/h for two hours
Study: 11943970
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention with weekly visits until 6 months postpartum and biweekly visits from 6 to 18 months
Study: 11943970
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with brief monthly tracking visits
Study: 9743270
Drug: Modafinil (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (exact dosage and duration not specified)
Study: 7707852
Drug: Sequential portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential portal and arterial reperfusion
Study: 608538
Drug: Corynebacterium parvum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum, 5 mg/m2 i.v.
Study: 30986119
Drug: 0.05% Cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Cyclosporin A topical nanoemulsion
Study: 29961848
Drug: Community scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) plus IPTp-SP
Study: 29961848
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of IPTp-SP doses
Study: 30187739
Drug: Without treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without treatment (A0)
Study: 21557241
Drug: Injection laryngoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection laryngoplasty
Study: 2650700
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of n-3 fatty acids
Study: 2650700
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high doses of n-3 fatty acids
Study: 2650700
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of n-3 fatty acids
Study: 69143
Drug: Intravenous aminoacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminoacids
Study: 69143
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat
Study: 18392675
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone co-treatment (4 mg daily subcutaneous injection from day 21 of preceding cycle until hCG)
Study: 18392675
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone co-treatment
Study: 18392675
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same treatment protocol without growth hormone)
Study: 9720330
Drug: i.v. fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fentanyl 0.1 mg followed by bolus injection of cold propofol premixed with lidocaine (final concentration of lidocaine was 0.2%) in a forearm vein without carrier i.v. fluid
Study: 9720330
Drug: Induction dose
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose of propofol via a vein on the dorsum of the hand at a slow injection speed with carrier i.v. fluid
Study: 2527891
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with nortriptyline or phenelzine
Study: 51958
Drug: Recombinant WRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant WRL 105 vaccine (10^7.0 E.I.D.50 administered as nose drops)
Study: 51958
Drug: Recombinant WRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant WRL 105 vaccine
Study: 25499666
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35-mg capsules under fasting conditions
Study: 25499666
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35-mg capsules under fed conditions
Study: 25499666
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac potassium IR 50-mg tablets under fasting conditions
Study: 25499666
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac potassium IR 50-mg tablets under fed conditions
Study: 23781136
Drug: Procalcitonin-guided antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided antibiotic therapy (threshold of 0.25 ng/ml)
Study: 23781136
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (standard practice)
Study: 21543343
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg/d)
Study: 21543343
Drug: Resistant Starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Starch (30 g/d)
Study: 21543343
Drug: Exploratory endpoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory endpoint - Resistant Starch (30 g/d)
Study: 19221977
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg pinitol
Study: 11773285
Drug: Inclusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclusion of anthracyclines in adjuvant chemotherapy regimens
Study: 11773285
Drug: Adjuvant dose-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer
Study: 9731961
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% ointment bd for 2 weeks followed by calcipotriol 50 microg/g bd for 4 weeks
Study: 9731961
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg/g bd for 6 weeks
Study: 30342299
Drug: First-line AAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line AAD therapy
Study: 24969718
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional treatment and care)
Study: 22643350
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg
Study: 22643350
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Study: 22643350
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ETV + TDF)
Study: 22643350
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Study: 20814005
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the early group (3 to 9 months post-stroke)
Study: 20814005
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the delayed group (15 to 21 months post-stroke)
Study: 18514770
Drug: Urine tumor-associated
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine tumor-associated trypsin inhibitor (TATI)
Study: 12560298
Drug: remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 3 microg x kg(‐1) followed by propofol 2 mg x kg(‐1) (Group I)
Study: 12560298
Drug: thiopentone 6
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiopentone 6 mg x kg(‐1) (Group II)
Study: 12560298
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg x kg(‐1) (Group III)
Study: 10868866
Drug: intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive insulin therapy + placebo (C) (n = 12)
Study: 10868866
Drug: intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive insulin therapy + nicotinamide, 700 mg three times a day (NIC) (n = 11)
Study: 10868866
Drug: 72‐h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72‐h intravenous insulin followed by intensive insulin therapy + nicotinamide, 700 mg three times a day (NIV) (n = 11)
Study: 9413735
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.3 g (kg body mass)‐1) 3 h before exercise
Study: 8105519
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline and salbutamol
Study: 3517081
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and Diazepam combination
Study: 30570529
Drug: alanine aminotransferase
Normalized name: Alanine aminotransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: alanine aminotransferase ≥36 IU/L
Study: 22585774
Drug: Oral dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dimenhydrinate (1 mg/kg; maximum: 50 mg) every 6 hours for 4 doses
Study: 22585774
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 doses
Study: 17570789
Drug: Lymphatic sparing
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic sparing (LS) technique with patent blue V dye (2 mL injected under the tunica dartos)
Study: 12376274
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone injections at 10 mg
Study: 7437265
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dapsone (DDS) + 25 mg pyrimethamine (PYR)
Study: 7437265
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dapsone (DDS)
Study: 30267864
Drug: Infliximab monotherapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab monotherapy (5 mg/kg)
Study: 30267864
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with infliximab and azathioprine (2.5 mg/kg/day)
Study: 30267864
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with infliximab and azathioprine
Study: 15459609
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment combined with streptokinase (HBO+)
Study: 2964548
Drug: NA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA infusion
Study: 31526307
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (1 mg/g of body weight)
Study: 29173128
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (CBT) plus an individually tailored intervention module focused on cognitive conflicts (CCs)
Study: 19499865
Drug: Coopdech blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coopdech blocker
Study: 7530697
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of L-697,639 (25 mg to 500 mg)
Study: 7530697
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of L-697,639 (up to 100 mg every 12 h for ten days)
Study: 7530697
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of L-697,639 (200 mg and 500 mg)
Study: 7530697
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of L-697,639 (25 mg and 500 mg)
Study: 7530697
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of L-697,639
Study: 7530697
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dose of L-697,639
Study: 14980912
Drug: Late ambulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late ambulation (Group L)
Study: 3278234
Drug: Tetracycline ointment
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline ointment
Study: 23756271
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg oral misoprostol (two 25 µg tablets)
Study: 23756271
Drug: 25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg intravaginal misoprostol (one 25 µg tablet)
Study: 12701817
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (30 g per day for 14 days)
Study: 2132029
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen infusion (0.3 g/body weight kg/day)
Study: 2132029
Drug: Low nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nitrogen infusion (0.1 g/body weight kg/day)
Study: 24907873
Drug: levobupivacaine 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 6.75 mg + 0.3 mL 2% lidocaine (Group L)
Study: 24907873
Drug: levobupivacaine 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 6.75 mg + saline (Group C)
Study: 20308916
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion during cardiopulmonary bypass (CPB)
Study: 20308916
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (control) during cardiopulmonary bypass (CPB)
Study: 25196873
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF), specific dosage and duration not mentioned
Study: 25196873
Drug: Corticosteroid treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment, specific dosage and duration not mentioned
Study: 15692468
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% applied twice daily for 2 years
Study: 7758229
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 12 months